SDC2 gene methylation detection primer probe system and kit thereof

Through the SDC2 gene methylation detection primer probe system and kit, PCR detection is performed using feces or blood samples, which solves the problem of invasiveness and low detection sensitivity in colorectal cancer screening, and achieves a non-invasive, fast and accurate early stage. Screening effect.

CN119020495AInactive Publication Date: 2024-11-26RENKUAN(SHANGHAI)SHENGWUKEJIYOUXIANGONGSI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411453690.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-17
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing colorectal cancer screening methods such as colonoscopy are highly invasive, the sensitivity and specificity of fecal occult blood detection are not ideal, and there is a lack of non-invasive, non-invasive and high detection rate detection methods.

Method used

Develop the SDC2 gene methylation detection primer probe system and its kit, using fecal samples or peripheral blood samples, through PCR reaction and fluorescent probe technology, to detect the methylation status of the SDC2 gene, providing non-invasive and rapid early screening method.

Benefits of technology

It has achieved non-invasive and non-invasive early screening of colorectal cancer, improved detection sensitivity and specificity, made easy to operate, reduced false positives and false negatives, and has a wide range of applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020495A_ABST
    Figure CN119020495A_ABST
Patent Text Reader

Abstract

The invention discloses an SDC2 gene methylation detection primer probe system and a kit thereof. The SDC2 gene methylation detection primer probe system comprises an amplification primer pair, a probe a for detecting methylated genes and a probe a'for detecting unmethylated genes, the amplification primer pair comprises an upstream primer and a downstream primer, the nucleotide sequences of the upstream primer and the downstream primer are as shown in SEQ ID NO.1-SEQ ID NO.2, the nucleotide sequence of the probe a is as shown in SEQ ID NO.3, and the nucleotide sequence of the probe a'is as shown in SEQ ID NO.4; different reporter fluorophores are arranged at the 5'ends of the probe a and the probe a '. According to the SDC2 gene methylation detection primer probe system and the kit thereof, invasive inspection is not needed, the public acceptability is high, and discomfort and risks caused by invasive operation are avoided; the kit is non-invasive in early screening of colorectal cancer, is high in detection sensitivity, reduces false positive and false negative, and is suitable for a wide range of people.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a primer probe system for detecting methylation of an SDC2 gene and a kit thereof. Background Art

[0002] Syndecan-2 (SDC2), also known as fibroglycan, was first discovered on the surface of lung fibroblasts and is a member of the heparin sulfate proteoglycan family on the cell surface. The heparin sulfate proteoglycan family also includes SDC1, SDC3 and SDC4, all of which are single transmembrane proteoglycans. Existing studies have shown that SDC2 is involved in a variety of biological processes. Early studies focused on revealing the function of SDC2 in cell adhesion and signal transduction (Jiang Naigui. Construction and identification of eukaryotic expression vector of SDC2, an important functional gene of esophageal cancer [D]. Guangdong: Shantou University, 2011.). SDC2 methylation is an early molecular event in promoting the development of colorectal tumors.

[0003] DNA methylation is one of the more mature markers in early cancer screening. DNA methylation is the conversion of cytosine to 5-methylcytosine under the action of DNA methyltransferase. Since 2019, SDC2 methylation detection has been used as an important means of detecting colorectal cancer. SDC2 gene methylation detection technology products have been successively included in the "Expert Consensus on the Screening Process for Early Colorectal Cancer in China (2019, Shanghai)", "China Hemorrhoids Diagnosis and Treatment Guidelines 2020" and "Chinese Expert Consensus on Laboratory Diagnosis Technology for Early Colorectal Cancer and Precancerous Lesions", becoming an important means of colorectal cancer screening in China. It has now entered more than 600 medical institutions, including more than 300 tertiary hospitals, and has won unanimous recognition from experts and examinees in various clinical departments, laboratories, health management departments and other related departments. In 2022, the National Medical Products Administration's Center for Medical Devices and Equipment Evaluation published an article entitled "Key Points for Technical Review of Clinical Trial Data for Human SDC2 Gene Methylation Detection Reagents", which further verified the value of SDC2 in early diagnosis and screening of colorectal cancer. Compared with traditional screening methods (fecal occult blood, colonoscopy, etc.), the SDC2 gene methylation test kit has the advantages of strong specificity, early, non-invasive and high detection rate.

[0004] According to the 2022 National Cancer Report released by the National Cancer Center, colorectal cancer accounts for 40.8% of cancers in my country, ranking second among malignant tumors. As one of the most common tumors in my country, early screening and early diagnosis of colorectal cancer are crucial to the survival of patients. In the early stage of colorectal cancer, there are no symptoms, or the symptoms are not obvious, only discomfort, indigestion, occult blood in the stool, etc. As the tumor develops, symptoms gradually appear, manifested as changes in bowel habits, abdominal pain, blood in the stool, abdominal mass, intestinal obstruction, etc., with or without systemic symptoms such as anemia, fever and weight loss. Tumors can cause changes in affected organs due to metastasis and infiltration. Colorectal cancer shows different clinical symptoms and signs due to its different sites of occurrence. There are two traditional methods for early screening of colorectal cancer, one is fecal occult blood test, and the other is colonoscopy. Fecal DNA colorectal cancer detection It is a new screening method with a sensitivity of 84.22% and a specificity of 97.85% for overall colorectal cancer. It can detect advanced adenomas and colorectal cancer lesions with a diameter of more than 1 cm, and detect early colorectal cancer gene mutations in time. A multicenter clinical trial in China (Molecular Diagnostics Group of the Laboratory Medicine Branch of the Chinese Medical Association. Expert consensus on experimental diagnostic techniques for early colorectal cancer and precancerous lesions in China) showed that the detection of SDC2 gene methylation in human colorectal cancer has a sensitivity of 83.8% for stage I-IV colorectal cancer, 87% for stage I-II that can be cured clinically, and 42.1% for adenomas larger than 1 cm, with an overall compliance rate of 93.6% with colonoscopy. Two domestic guidelines and expert consensus have included this test in the early screening recommendations for colorectal cancer. This test is not only used for early non-invasive screening of colorectal cancer in the population, but can also be used for regular clinical laboratory monitoring of patients after colorectal cancer surgery to promptly detect postoperative recurrence.

[0005] At present, colonoscopy is the gold standard for colorectal cancer detection, but it is invasive to a certain extent; although fecal occult blood test is a non-invasive screening method, its sensitivity and specificity are not ideal. Therefore, it is urgent to develop a new product to meet the market demand. Summary of the invention

[0006] Technical problems to be solved: In response to the above technical problems, the present invention provides a SDC2 gene methylation detection primer probe system and a kit thereof, which does not require invasive examination, can use stool samples or peripheral blood samples, and is convenient and simple to sample, and has a high degree of public acceptance; it uses molecular detection methods, and has the advantages of being non-invasive and having high detection sensitivity for early screening of colorectal cancer.

[0007] Technical solution: In the first aspect, the present invention provides a primer-probe system for detecting methylation of the SDC2 gene, comprising an amplification primer pair, a probe a for detecting methylated genes, and a probe a' for detecting unmethylated genes; the amplification primer pair comprises an upstream primer and a downstream primer, and the nucleotide sequences thereof are shown in SEQ ID NO.1-SEQ ID NO.2, the nucleotide sequence of probe a is shown in SEQ ID NO.3, and the nucleotide sequence of probe a' is shown in SEQ ID NO.4; different reporter fluorescent groups are provided at the 5' ends of the probe a and the probe a'.

[0008] Preferably, the final concentration of each primer used in the PCR reaction is 900 nM, and the final concentration of each probe used in the PCR reaction is 250 nM.

[0009] Preferably, the reporter fluorescent group is FAM or VIC.

[0010] Preferably, the probability of SDC2 gene methylation = the number of copies of the fluorescence carried by the reporter probe a ÷ (the number of copies of the fluorescence carried by the reporter probe a + the number of copies of the fluorescence carried by the reporter probe a').

[0011] In a second aspect, the present invention provides a SDC2 gene methylation detection kit comprising the primer-probe system described in the first aspect.

[0012] Beneficial effects: The SDC2 gene methylation detection primer probe system and kit of the present invention do not require invasive examination, can use stool samples or peripheral blood samples, sampling is convenient and simple, and the public acceptance is relatively high; it uses molecular detection methods, and has the advantages of non-invasiveness and high detection sensitivity for early screening of colorectal cancer. In addition, the kit of the present invention is relatively quick to operate, with high patient compliance, avoiding the discomfort and risks caused by invasive operations, and can accurately identify and reduce the occurrence of false positives and false negatives, and is suitable for a wide range of people. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 is a schematic diagram of the test results of sample 1 in Example 1 of the present invention; Figure 2 It is a schematic diagram of the detection results of sample 2 in Example 1 of the present invention. DETAILED DESCRIPTION

[0014] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments: Example 1

[0015] The steps of using the primer-probe system of the present invention to detect the methylation probability of the sample to be tested (the sample verified by pyrophosphate sequencing and BSP sequencing) are as follows: 1. Pretreatment of the sample to be tested: Use a DNA methylation modification kit (EZ DNA Methylation-Lightning, KitZYMO RESEARCH) to treat the DNA of the sample to be tested with sulfite to obtain a sulfite-treated sample; 2. Synthesize primers and probes: According to the sequence in Table 1 below, entrust Nanjing Kebai Biotechnology Co., Ltd. to complete the synthesis.

[0016] Table 1 Primer-probe system of the present invention

[0017] Note: The 5' end of the probe SDC2-Methy-PC is modified with FAM, and the 5' end of the probe SDC2-Methy-PC is modified with VIC.

[0018] 3. Use Bio-Rad's ddPCR supermix for probes to test the samples after sulfite treatment: 3.1. Prepare the PCR reaction system as shown in Table 2 below: Table 2 PCR reaction system

[0019] Note: The concentration of the DNA after sulfite treatment is 50 ng / μL, the concentrations of the upstream primer and the downstream primer in the amplification primer pair are both 900 nM, and the concentrations of probes a and a' are both 250 nM.

[0020] 3.2. The setting of the reaction program is shown in Table 3 below: Table 3 PCR reaction procedure

[0021] Note: The heating rate is 2°C / sec., the cover temperature is set to 105°C, and the sample volume is set to 40 μL.

[0022] 3.3 Results and Analysis The experimental results are as follows Figure 1-Figure 2 The corresponding data are shown in Table 4 below: Table 4 Experimental results

[0023] The results show that the method of the present invention can directly quantify the methylation probability, has higher efficiency, and the data is more intuitive. In addition, compared with other sequencing methods, the method of the present invention takes less time and is more efficient. Example 2

[0024] Positive samples and negative samples were mixed in different proportions, as shown in Table 5 below, and the primer-probe system of the present invention was used for detection according to Example 1. Table 5 Sample combinations with different proportions and test results

[0025] The results show that the probe of the present invention exhibits high specificity and appropriate sensitivity during the detection process and is capable of detecting the target substance in the positive sample. Example 3

[0026] Low-frequency samples were prepared and tested using the primer-probe system of the present invention according to Example 1. The results are shown in Table 6 below: Table 6 Low-frequency samples and their detection results

[0027] As shown in Table 6, the error between the theoretical value and the actual value is within 5%, and the sensitivity and specificity of the primer probe are relatively ideal, which can accurately reflect the situation of the sample. It can be further explained that even for low-copy and low-concentration samples, the accuracy and sensitivity of the detection can be guaranteed.

[0028] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. The SDC2 gene methylation detection primer probe system is characterized by: It includes an amplification primer pair, a probe a for detecting methylated genes, and a probe a' for detecting unmethylated genes; The amplification primer pair includes an upstream primer and a downstream primer, the nucleotide sequences of which are shown in SEQ ID NO.1-SEQ ID NO.2, the nucleotide sequence of probe a is shown in SEQ ID NO.3, and the nucleotide sequence of probe a' is shown in SEQ ID NO.4; The 5' ends of the probe a and the probe a' are provided with different reporter fluorescent groups.

2. The SDC2 gene methylation detection primer-probe system according to claim 1, characterized in that: The final concentration of each primer used in the PCR reaction was 900 nM, and the final concentration of each probe used in the PCR reaction was 250 nM.

3. The SDC2 gene methylation detection primer-probe system according to claim 1, characterized in that: The reporter fluorescent group is FAM or VIC.

4. The SDC2 gene methylation detection primer-probe system according to claim 1, characterized in that: The probability of SDC2 gene methylation = the number of copies of the fluorescence carried by reporter probe a ÷ (the number of copies of the fluorescence carried by reporter probe a + the number of copies of the fluorescence carried by reporter probe a').

5. A SDC2 gene methylation detection kit comprising the primer-probe system according to any one of claims 1 to 4.

Citation Information

Patent Citations

  • Detection primer for methylation degree of related genes of cervical cancer, probe, kit and application thereof

    CN107287294A

  • A DNA methylation degree quantifying method and application

    CN109022556A

  • Quantification system for DNA methylation

    CN109385465A

  • Kit for quantitative detection of EB virus Cp promoter methylation

    CN114574631A

  • Gastric cancer gene methylation detection kit and detection method

    CN117431320A